

Date: October 21, 2026

To,

The Manager
Listing Department
National Stock Exchange of India Limited (NSE)
Exchange Plaza, 5th Floor
Plot No. C/1, G-Block
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
Symbol: SAGILITY

The Manager
Listing Department
BSE Limited (BSE)
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code:544282

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We wish to inform you that the Board of Directors of the Company at their meeting held on 21st October 2026, have proposed an acquisition/investment by Sagility (US) Holdings Inc., a wholly owned subsidiary of Sagility Limited. Sagility (US) Holdings Inc., has signed a definitive agreement on 21st October 2026, with Chirok Health LLC, the details of which are given as Annexure A to this letter, as required under the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Kindly take the above information on your record

For Sagility Limited

SATISHKUMAR
SAKHARAYAPATTANA
A SEETHARAMAIAH

Digitally signed by SATISHKUMAR
SAKHARAYAPATTANA
SEETHARAMAIAH
Date: 2026.10.21 20:52:26 +05'30'

Satishkumar Sakharayapattana Seetharamaiah
Company Secretary & Compliance Officer
Membership No: A16008

Place: Bengaluru

Sagility Limited

(Formerly Sagility India Limited)

Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India

Corporate Identification Number: L72900KA2021PLC150054

Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com

Annexure A

Details as required under SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sl. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Chirok Health LLC Turnover: US\$ 9.0 M (CY2025) here hereafter mentioned as Chirok
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
3	Industry to which the entity being acquired belongs.	Healthcare services / Healthcare Revenue Cycle Management (RCM), including Clinical Documentation Integrity (CDI) and medical coding services.
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition is intended to strengthen Sagility’s capabilities in the provider segment by adding specialised Clinical Documentation Integrity (CDI), medical coding and revenue optimisation capabilities, complementing Sagility’s existing healthcare services portfolio.
5	Brief details of any governmental or regulatory approvals required for the acquisition	NA
6	Indicative time-period for completion of the acquisition	21 st October 2026
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8	Cost of acquisition and/or the price at which the shares are acquired	Aggregate purchase consideration of upto US\$ 32.35 M, comprising: Upfront payment of US\$ 20.0 M at closing, subject to customary closing adjustments; and

Sagility Limited

(Formerly Sagility India Limited)

Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India

Corporate Identification Number: L72900KA2021PLC150054

Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com

		Contingent consideration upto US\$ 12.35 M, payable subject to achievement of specified performance milestones
9	Percentage of shareholding / control acquired and / or number of shares acquired	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	Chirok Health LLC is a US-based healthcare services company providing Clinical Documentation Integrity (CDI), medical coding, Revenue Cycle Management (RCM), and audit and quality assurance services, supported by its proprietary CHEMP workflow platform. The Company was incorporated in 2019 and is headquartered in Tennessee, United States. The Company has turnover of approximately USD 12.7 M, USD 8.2 M, and USD 9.0 M for CY2023, CY2024, and CY2025 respectively.

Sagility Limited

(Formerly Sagility India Limited)

Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India

Corporate Identification Number: L72900KA2021PLC150054

Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagility.com